Revvity, Inc. (RVTY) News
Track canonical SquawkNews coverage tagged to RVTY, Revvity, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Revvity reports Q2 revenue, raises FY guide; expands diagnostics
Revvity (RVTY) reported Q2 revenue of $730M (pro forma +4%), raised FY guidance to $2.83–$2.86B (pro forma ~4–5% growth), and launched SuperFlex prenatal testing, expanded preeclampsia diagnostic coverage, and moved the
EQUITY | Sep 21, 2026, 11:29 AM UTC
M
Biotech shares hit 52-week highs; MNOV, RVTY, TLX jump
Several biotech stocks reached 52-week highs on Sept. 15, 2026, including MediciNova (MNOV), Revvity (RVTY), and Telix (TLX), with the report attributing strength to gains on certain clinical or financial results.
EQUITY | Sep 16, 2026, 05:36 AM UTC
L
RVTY: Diagnostics and life sciences growth, AI-driven innovation, and strong backlog fuel positive outlook
The company reported strong Q2 results, driven by diagnostics and a recovering life sciences segment, with significant backlog in high-content screening instruments and robust growth in China. Software innovation and AI
EARNINGS | Sep 15, 2026, 02:35 PM UTC
L
RVTY: Strong Q2 results, innovation, and AI-driven demand set the stage for Revvity's growth
Revvity reported better-than-expected Q2 results, driven by strong diagnostics and a robust backlog in life sciences, especially high-content screening instruments. Innovation in software and AI integration, along with o
EARNINGS | Sep 15, 2026, 02:06 PM UTC
H
RVTY raises margin guidance as AI-driven demand lifts growth
AI-driven demand is accelerating growth in high-content screening and software, while a tuck-in acquisition strengthens the reagents portfolio. Diagnostics and reproductive health segments remain robust, and margin guida
EARNINGS | Sep 09, 2026, 02:24 PM UTC
L
UBS assumes neutral on Revvity, raises price target to $140
UBS coverage on Revvity is assumed at a neutral rating versus a previous buy, with the price target raised to $140.00 per share from $120.00.
EQUITY | Sep 09, 2026, 02:06 PM UTC
H
RVTY raises margin guidance on AI-driven demand and cost initiatives
RVTY cites AI-driven demand for high-content screening and software innovation, plus robust diagnostics and reproductive health growth. It also says a tuck-in reagents acquisition supports the reagents business, and rais
EARNINGS | Sep 09, 2026, 01:45 PM UTC
L
Revvity to acquire Human Cell Design
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
MNA | Sep 09, 2026, 10:51 AM UTC
M
Revvity to acquire Human Cell Design to advance metabolic disease models
Revvity plans to acquire Human Cell Design to advance human-relevant cell models for metabolic disease drug discovery.
MNA | Sep 09, 2026, 10:04 AM UTC
L
Revvity files additional transaction terms not disclosed
Revvity reports additional terms of transaction are not disclosed for RVTY.
EQUITY | Sep 09, 2026, 10:01 AM UTC
L
Revvity price target raised to $165 by Keybanc
Keybanc raised its Revvity price target to $165.00/share from $125.00, according to Benzinga ratings actions.
EQUITY | Sep 04, 2026, 01:27 PM UTC
L
RBC Capital starts Revvity at Sector Perform
RBC Capital initiated coverage of Revvity with a Sector Perform rating.
EQUITY | Sep 01, 2026, 12:13 PM UTC
H
Transcript: Revvity Q2 2026 Earnings Conference Call
Revvity (NYSE: RVTY ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to l
EARNINGS | Aug 04, 2026, 12:34 PM UTC
H
Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 Sales Guidance from $2.810B-$2.840B to $2
Revvity (NYSE: RVTY ) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst estimate. Raises FY2026 sales outlook from $2.810 billion-$2.840 billion to $2.830 billion-$2.860 billion vs $2.858 bi
EARNINGS | Aug 04, 2026, 10:02 AM UTC
H
RVTY - Revvity Announces Financial Results for the Second Quarter of 2026
RVTY - Revvity Announces Financial Results for the Second Quarter of 2026
EARNINGS | Aug 04, 2026, 10:01 AM UTC
L
Revvity Declares Quarterly Dividend
Revvity declares quarterly dividend
EQUITY | Jul 31, 2026, 08:10 PM UTC
L
Evercore ISI Adjusts Price Target on Revvity to $125 From $110
() -- Revvity (RVTY) has an average rating of overweight and mean price target of $114.21, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in
EQUITY | Jul 06, 2026, 01:10 PM UTC
M
RVTY: Bernstein Reinstates
Bernstein reinstates Market Perform on Revvity with a $115 price target
EQUITY | Jun 26, 2026, 01:18 PM UTC